Ting Zhang

Ting Zhang

Auto-generated profile, based on publicly available information

Ting Zhang

School of Basic Medicine, Harbin Medical Hospital, Harbin, Heilongjiang, People's Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
JJJinjiang Jiang
Jinjiang Jiang
BCBo Chen
Bo Chen
BTBo Tang
Bo Tang
JYJie Yang
Jie Yang
TZTing Zhang
Ting Zhang
QWQiang Wei
Qiang Wei
Background: Our study was designed to elucidate the morbidity trends of prostate cancer in low-incidence countries. Methods: Data on prostate cancer were extracted from the 2019 Global Burden of Disease study. A cluster analysis of growth rates stratified by age was conducted, and correlation analyses were performed between age-standardized incidence rates (ASIR), estimated annual percent change (EAPC), and socio-demographic index (SDI). Results: Among 35 low-incidence countries for prostate cancer, predominantly located in Asia and North Africa, the SDI ranged from low to high-middle levels. Higher SDI regions exhibited considerably higher ASIR. With the exception of Kyrgyzstan, Kiribati, and Samoa that experienced a decrease in ASIR, the remaining 32 countries displayed an upward morbidity trend since 1990, with all their EAPCs exceeding the global average. In addition, men ages 90 years and above consistently exhibited the highest ASIR for prostate cancer. The most notable growth rate of ASIR was observed in individuals ages 20 to 44 years. Conclusions: Overall, low-incidence countries generally witnessed an increase in prostate cancer morbidity, albeit at levels lower than those seen in Western countries. Individuals ages 90 years and above consistently maintained the highest ASIR since 1990. Notably, more substantial increase of ASIR in younger age was also observed in low-incidence countries. Impact: This study offers a comprehensive overview of prostate cancer morbidity in low-incidence countries worldwide from 1990 to 2019. Future research should delve into the associations between incidence, clinical stages, PSA screening, environmental factors, lifestyle, and genetic risk in these low-incidence countries.

6 February 2024
Verified
Other
Open access
JJJinjiang Jiang
Jinjiang Jiang
BCBo Chen
Bo Chen
BTBo Tang
Bo Tang
JYJie Yang
Jie Yang
TZTing Zhang
Ting Zhang
QWQiang Wei
Qiang Wei
Supplementary Figure S2 shows the age-specific burden of prostate cancer among Afghanistan, Algeria, Bangladesh, Bhutan, China, Democratic People's Republic of Korea in 1990 and 2019. (a) Minor variations in the age distribution of prostate cancer in Afghanistan were observed between 1990 and 2019. In 1990, the highest ASIR was observed in the 90-94 years age group, while by 2019, it had shifted to the 95+ years age group. (b) Algeria exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 95+ years age group having the highest ASIR in both years. (c) Bhutan exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 95+ years age group having the highest ASIR in both years. (d) Bangladesh exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 95+ years age group having the highest ASIR in both years. (e) Democratic People's Republic of Korea exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 95+ years age group having the highest ASIR in both years.(f) China exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years.

6 February 2024
Verified
Other
Open access
JJJinjiang Jiang
Jinjiang Jiang
BCBo Chen
Bo Chen
BTBo Tang
Bo Tang
JYJie Yang
Jie Yang
TZTing Zhang
Ting Zhang
QWQiang Wei
Qiang Wei
Supplementary Figure S5 shows the age-specific burden of prostate cancer among Mozambique, Myanmar, Nepel, Pakistan, Sri Lanka, Sudan in 1990 and 2019.(a) Sudan exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years. (b) Mozambique exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years. (c) Sri Lanka exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 95+ years age group having the highest ASIR in both years. (d) Nepal exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 95+ years age group having the highest ASIR in both years. (e) Minor variations in the age distribution of prostate cancer in Pakistan were observed between 1990 and 2019. In 1990, the highest ASIR was observed in the 90-94 years age group, while by 2019, it had shifted to the 95+ years age group. (f) Myanmar exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years.

6 February 2024
Verified
Other
Open access
JJJinjiang Jiang
Jinjiang Jiang
BCBo Chen
Bo Chen
BTBo Tang
Bo Tang
JYJie Yang
Jie Yang
TZTing Zhang
Ting Zhang
QWQiang Wei
Qiang Wei
Background:Our study was designed to elucidate the morbidity trends of prostate cancer in low-incidence countries.Methods:Data on prostate cancer were extracted from the 2019 Global Burden of Disease study. A cluster analysis of growth rates stratified by age was conducted, and correlation analyses were performed between age-standardized incidence rates (ASIR), estimated annual percent change (EAPC), and socio-demographic index (SDI).Results:Among 35 low-incidence countries for prostate cancer, predominantly located in Asia and North Africa, the SDI ranged from low to high-middle levels. Higher SDI regions exhibited considerably higher ASIR. With the exception of Kyrgyzstan, Kiribati, and Samoa that experienced a decrease in ASIR, the remaining 32 countries displayed an upward morbidity trend since 1990, with all their EAPCs exceeding the global average. In addition, men ages 90 years and above consistently exhibited the highest ASIR for prostate cancer. The most notable growth rate of ASIR was observed in individuals ages 20 to 44 years.Conclusions:Overall, low-incidence countries generally witnessed an increase in prostate cancer morbidity, albeit at levels lower than those seen in Western countries. Individuals ages 90 years and above consistently maintained the highest ASIR since 1990. Notably, more substantial increase of ASIR in younger age was also observed in low-incidence countries.Impact:This study offers a comprehensive overview of prostate cancer morbidity in low-incidence countries worldwide from 1990 to 2019. Future research should delve into the associations between incidence, clinical stages, PSA screening, environmental factors, lifestyle, and genetic risk in these low-incidence countries.

6 February 2024
Verified
Other
Open access
JJJinjiang Jiang
Jinjiang Jiang
BCBo Chen
Bo Chen
BTBo Tang
Bo Tang
JYJie Yang
Jie Yang
TZTing Zhang
Ting Zhang
QWQiang Wei
Qiang Wei
Supplementary Figure S4 shows the age-specific burden of prostate cancer among Libya, Malawi, Mali, Maldives, Mongolia, Morocco in 1990 and 2019.(a) Morocco exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years. (b) Libya exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 95+ years years age group having the highest ASIR in both years. (c) Mongolia exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years age group having the highest ASIR in both years. (d) Variations in the age distribution of prostate cancer in Maldives are evident between 1990 and 2019. In 1990, the highest ASIR was observed in the 90-94 years age group, while by 2019, it had shifted to the 80-84 years age group. (e) Malawi exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years. (f) Mali exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years.

6 February 2024
Verified
Other
Open access
JJJinjiang Jiang
Jinjiang Jiang
BCBo Chen
Bo Chen
BTBo Tang
Bo Tang
JYJie Yang
Jie Yang
TZTing Zhang
Ting Zhang
QWQiang Wei
Qiang Wei
Supplementary Figure S3 shows the age-specific burden of prostate cancer among Egypt, Ethiopia, Gambia, India, Iraq, Lao People's Democratic Republic in 1990 and 2019.(a) Minor variations in the age distribution of prostate cancer in Egypt were observed between 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years. (b) Variations in the age distribution of prostate cancer in Lao People's Democratic Republic are evident between 1990 and 2019. In 1990, the highest ASIR was observed in the 90-94 years age group, while by 2019, it had shifted to the 80-84 years age group. (c) Iraq exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years age group having the highest ASIR in both years. (d) Minor variations in the age distribution of prostate cancer in India were observed between 1990 and 2019. In 1990, the highest ASIR was observed in the 90-94 years age group, while by 2019, it had shifted to the 95+ years age group.(e) Ethiopia exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years. (f) Gambia exhibits a consistent age structure for prostate cancer in both 1990 and 2019, with the 90-94 years years age group having the highest ASIR in both years.